Phase 1 Study Evaluating Genetically Modified Autologous T-cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients with Recurrent and/or Refractory Solid Tumors (ACTengine IMA202-101)
Study of T-Cells (IMA202-101) Given in Combination with Chemotherapy to Patients with Solid Tumors
Sponsor: Immatics
Enrolling: Male and Female Patients
IRB Number: AAAS6578
U.S. Govt. ID: NCT03441100
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The goal of the overall study is to learn if it is safe to give genetically changed T cells (IMA202) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with melanoma solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA202 and if the study drug can help to control the disease.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have recurrent (come back) or refractory (does not respond to treatment) melanoma? Yes No
Are you willing to undergo testing, such as biopsies and blood draws? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE